iCAD, Inc. Release: Researchers To Present Up To 5-Year Positive Clinical Data Supporting Use Of Xoft System For Early-Stage Breast Cancer And Nonmelanoma Skin Cancer At ASTRO 2015

NASHUA, N.H. and SAN ANTONIO, Oct. 19, 2015 /PRNewswire/ -- (Booth #423) - iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, will present updated clinical data, host in-booth clinician presentations and showcase the latest in radiation technology at the American Society for Radiation Oncology (ASTRO) meeting in San Antonio, TX from October 18-21, 2015.

"ASTRO 2015 represents an important milestone where researchers are sharing the most recent, and longest-term data available supporting the use of the Xoft System for the treatment of both early-stage breast cancer and nonmelanoma skin cancer (NMSC)," said Ken Ferry, CEO of iCAD. "iCAD is committed to remaining at the forefront of innovation and research, and we look forward to sharing with our colleagues new data showing the advantages of the Xoft System for the treatment of an even wider variety of cancers."

At the meeting, Dr. Ajay Bhatnagar and Dr. Parag Sanghvi will present posters with updated data on the use of eBx in the treatment of NMSC. Their data reflect treatment with the Xoft System for a total of 342 patients with 466 NMSC lesions, resulting in excellent cosmesis and few recurrences, with a mean follow up time of 16.5 months and 11.8 months, respectively.

Dr. Alam M. Nisar Syed and Dr. Adam Dickler will also present posters with data supporting use of the Xoft System for the treatment of early-stage breast cancer. Their data reflect treatment of 136 breast cancer lesions with the Xoft System, showing positive clinical results, excellent to good cosmesis, few recurrences, and a low rate of low-grade adverse events.

Posters will be presented in Poster Hall A from 10 am to 5 pm throughout the meeting; the Poster Viewing Reception will be from 5:30 pm to 6:45 pm on Monday, October 19.

• Electronic brachytherapy for the treatment of Non-Melanoma Skin Cancer: Results up to 5 years
  Poster # 3598
  Ajay Bhatnagar, MD, MBA, Medical Director, 21st Century Oncology of Arizona, Adjunct Assistant Professor of Radiation Oncology, University of Pittsburgh School of Medicine
• Clinical and Cosmetic Outcomes in Patients Treated With High Dose Rate Electronic Brachytherapy for Nonmelanoma Skin Cancer
  Poster #3589
  Parag Sanghvi, MD, MSPH, Assistant Professor, Radiation Oncology, University of California San Diego, San Diego, CA
• Feasibility and Early Outcomes of a Multi-Center Trial of Intra-Operative Radiation Therapy Using Electronic Brachytherapy at the Time of Breast Conservation Surgery for Early Stage Breast Cancer
  Poster #3464
  Alam M. Nisar Syed, MD, Medical Director, Radiation Oncology & Endocurietherapy,
  Memorial Care Cancer Institute Long Beach Memorial Medical Center
• Five Year Results of a Multi-Center Trial Utilizing Electronic Brachytherapy to Deliver Intraoperative Radiation Therapy in the Treatment of Early-Stage Breast Cancer
  Poster #2061
  Adam Dickler, MD, Medical Director of CyberKnife Cancer Institute of Chicago, Little Company of Mary Hospital

Gary Proulx MD, Medical Director, Exeter Hospital Radiation Oncology, Clinical Associate Professor, Massachusetts General Hospital, will discuss his clinical experience with IORT and the Xoft System at the Xoft booth in presentations at 12:30 pm and 3:50 pm on Monday, October 19.

The Xoft System will be available at booth #423 for demonstration purposes.  The Xoft System's cervical applicator, which is now commercially available, will also be showcased in the booth.  Visitors will also have an opportunity to see  an investigational line of applicators for intraoperative radiation therapy (IORT) that are being shown as works in progress for the treatment of prostate, head/neck, abdominal, and brain cancers, among others.

#HighTechHope: High Tech = High Hope
As part of its commitment to being a leader in medical technology, during ASTRO 2015 iCAD is launching a social media campaign aimed at supporting the ThriveWell Cancer Foundation, a San Antonio cancer support center. As this year's ASTRO meeting theme is High Tech = High Hope, iCAD is encouraging attendees to share what "high tech" innovations are giving them "high hope," using the tag @XoftiCAD and the hashtag #HighTechHope in social media posts. For each tweet or Facebook post using #HighTechHope, Xoft will make a donation to the ThriveWell Cancer Foundation, a San Antonio cancer support center, on your behalf. For more information about this campaign, visit http://www.xoftinc.com/hightechhope.htm.

For updates throughout ASTRO, follow the Xoft Twitter handle, @XoftiCAD. For additional information regarding iCAD and the technologies being discussed at ASTRO 2015, please visit www.xoftinc.com/ASTRO.htm. If you have a question about iCAD products, please contact us.

Tweets, retweets, mentions and replies, and Facebook posts and shares using the #HighTechHope hashtag during ASTRO 2015 (10/18/15 to 10/20/15) are eligible for donation.

Xoft, a subsidiary of iCAD, maintains a presence on Facebook, Twitter, LinkedIn and YouTube but is not affiliated with these social media sites and has no control over how these sites or other third parties will use the information shared on the site.  Neither the information, nor any opinion, on Facebook, Twitter, LinkedIn or YouTube constitutes a solicitation or offer by iCAD or its affiliates to buy or sell any securities. iCAD is not responsible for third parties that may be linked to its Facebook, Twitter, LinkedIn and YouTube pages, including but not limited to content posted by third parties, or for the products or services offered by any third party.

About Xoft Axxent Electronic Brachytherapy System
The Xoft System is an isotope-free radiation treatment that is FDA cleared, CE marked, and licensed in Canada for the treatment of cancer anywhere in the body, including treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. The Xoft System requires only minimal shielding and therefore does not require room redesign or construction investment. Minimal shielding also allows medical personnel to remain in the room with the patient during treatment. The mobility of the Xoft System makes it easy to treat patients at multiple locations and to easily store the system when not in use. Xoft is a wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit www.xoftinc.com, like us on Facebook or follow us on Twitter at @xofticad.

About iCAD, Inc.
iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD's Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared, CE marked, and licensed in Canada for the treatment of cancer anywhere in the body, including treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit or www.icadmed.com or www.xoftinc.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company's ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "will", "continue", "anticipate", "likely", "seek", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC's website at http://www.sec.gov.

Contact:

For iCAD investor relations:

The Ruth Group
Zack Kubow, 646-536-7030
www.theruthgroup.com
iCAD@theruthgroup.com

or

For iCAD media inquiries:

Berry & Company Public Relations, LLC
Jessica Burns, 212-253-8881
jburns@berrypr.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/researchers-to-present-up-to-5-year-positive-clinical-data-supporting-use-of-xoft-system-for-early-stage-breast-cancer-and-nonmelanoma-skin-cancer-at-astro-2015-300161647.html

SOURCE iCAD, Inc.